Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Takeda To Reclaim Sales Rights To Actos, Create Own Networks

This article was originally published in PharmAsia News

Executive Summary

Takeda Pharmaceutical plans to take back the sales rights to its key diabetes drug from Eli Lilly and create its own sales network in most of Europe, Canada and other countries outside Japan. Takeda already does its own selling of Actos (pioglitazone) in the United States, United Kingdom, France and other countries. Lilly had been marketing the drug in countries where Takeda lacked a sales network. Seven countries besides Canada are involved in the takeback--Belgium, Denmark, Luxembourg, Norway, Sweden and Turkey. (Click here for more - a subscription may be required



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts